CenterBook Partners LP Acquires 364,390 Shares of Roivant Sciences Ltd. $ROIV

CenterBook Partners LP grew its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 147.3% during the 4th quarter, Holdings Channel reports. The firm owned 611,833 shares of the company’s stock after purchasing an additional 364,390 shares during the period. Roivant Sciences makes up approximately 0.6% of CenterBook Partners LP’s portfolio, making the stock its 28th biggest position. CenterBook Partners LP’s holdings in Roivant Sciences were worth $13,277,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Clearbridge Investments LLC boosted its stake in shares of Roivant Sciences by 7.7% in the 4th quarter. Clearbridge Investments LLC now owns 1,972,921 shares of the company’s stock valued at $42,812,000 after purchasing an additional 141,549 shares during the last quarter. ING Groep NV bought a new position in shares of Roivant Sciences in the 4th quarter valued at about $12,768,000. Vise Technologies Inc. bought a new position in shares of Roivant Sciences in the 4th quarter valued at about $354,000. TD Asset Management Inc boosted its stake in shares of Roivant Sciences by 74.4% in the 4th quarter. TD Asset Management Inc now owns 551,376 shares of the company’s stock valued at $11,965,000 after purchasing an additional 235,176 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Roivant Sciences by 365.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after purchasing an additional 8,621,567 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Insider Buying and Selling at Roivant Sciences

In other news, CEO Matthew Gline sold 289,774 shares of Roivant Sciences stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $29.16, for a total value of $8,449,809.84. Following the sale, the chief executive officer directly owned 16,736,116 shares in the company, valued at $488,025,142.56. This trade represents a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Melissa B. Epperly sold 41,861 shares of Roivant Sciences stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $28.68, for a total transaction of $1,200,573.48. Following the completion of the sale, the director owned 15,804 shares in the company, valued at $453,258.72. This trade represents a 72.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 945,173 shares of company stock valued at $27,654,456 over the last ninety days. 10.80% of the stock is currently owned by company insiders.

Roivant Sciences Price Performance

Roivant Sciences stock opened at $28.58 on Monday. The company’s 50 day simple moving average is $28.76 and its 200 day simple moving average is $25.71. Roivant Sciences Ltd. has a fifty-two week low of $10.70 and a fifty-two week high of $32.79. The firm has a market capitalization of $20.56 billion, a price-to-earnings ratio of -47.63 and a beta of 1.13.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.57. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. The business had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. During the same quarter last year, the firm earned ($0.29) EPS. As a group, analysts predict that Roivant Sciences Ltd. will post -1.83 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on ROIV. Guggenheim lifted their price objective on shares of Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, May 26th. HC Wainwright reissued a “buy” rating and set a $34.00 price objective on shares of Roivant Sciences in a research note on Thursday, May 21st. TD Cowen lifted their price objective on shares of Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Weiss Ratings lowered shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Finally, Sanford C. Bernstein began coverage on shares of Roivant Sciences in a research note on Friday, March 20th. They set an “outperform” rating and a $35.00 price objective on the stock. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.59.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.